535-65-9

Basic information

• Product Name: glybuthiazol
• Synonyms: glybuthiazol;2259 R.P.;Glipasol;Glypasol;RP-2259;4-amino-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide;4-azanyl-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide
• CAS NO: 535-65-9
• Molecular Formula: C₁₂H₁₆N₄O₂S₂
• Molecular Weight: 312.416
• EINECS: 208-615-8
• Mol File: 535-65-9.mol
• Article Data: 2

Chemical Properties

• Melting Point: 221-223°
• Boiling Point: 506.3°Cat760mmHg
• Flash Point: 260°C
• Appearance: /
• Density: 1.3363 (rough estimate)
• Vapor Pressure: 2.25E-10mmHg at 25°C
• Refractive Index: 1.6440 (estimate)
• PKA: 5.52±0.50(Predicted)
• Water Solubility: 56.86mg/L(37 oC)
• CAS DataBase Reference: glybuthiazol(CAS DataBase Reference)
• NIST Chemistry Reference: glybuthiazol(535-65-9)
• EPA Substance Registry System: glybuthiazol(535-65-9)

Safety Data

• Hazardous Substances Data: 535-65-9(Hazardous Substances Data)

Usage

General Description

Glybuthiazol is a chemical compound that belongs to the thiazole class of organic compounds. It has been used in animal studies as an antidiabetic and anti-inflammatory agent, and has also been investigated for its potential in treating obesity and metabolic syndrome. Glybuthiazol has been shown to have insulin-sensitizing and glucose-lowering effects, and it may also have antioxidant and neuroprotective properties. However, further research is needed to fully understand its potential therapeutic uses and any potential risks associated with its use.

InChI:InChI=1/C12H16N4O2S2/c1-12(2,3)10-14-15-11(19-10)16-20(17,18)9-6-4-8(13)5-7-9/h4-7H,13H2,1-3H3,(H,15,16)

Upstream product

• 39222-73-6 2-Amino-5-t-butyl-1,3,4-thiadiazole 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 432539-49-6 N-(4-(N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamoyl)phenyl)acetamide 

Downstream Products

• 1191951-67-3 N-(4-(N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamoyl)phenyl)decanamide 

Relevant articles and documents

Development of sulfonamide AKT PH domain inhibitors

Disruption of the phosphatidylinositol 3-kinase/AKT signaling pathway can lead to apoptosis in cancer cells. Previously we identified a lead sulfonamide that selectively bound to the pleckstrin homology (PH) domain of AKT and induced apoptosis when present at low micromolar concentrations. To examine the effects of structural modification, a set of sulfonamides related to the lead compound was designed, synthesized, and tested for binding to the expressed PH domain of AKT using a surface plasmon resonance-based competitive binding assay. Cellular activity was determined by means of an assay for pAKT production and a cell killing assay using BxPC-3 cells. The most active compounds in the set are lipophilic and possess an aliphatic chain of the proper length. Results were interpreted with the aid of computational modeling. This paper represents the first structure-activity relationship (SAR) study of a large family of AKT PH domain inhibitors. Information obtained will be used in the design of the next generation of inhibitors of AKT PH domain function.